The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17. “Although the overall risk of being infected with mpox for the general EU population remains low, we are working continuously at EU level to ensure good preparedness,” EU Health Commissioner Stella Kyriakides said. Imvanex is the only mpox vaccine currently authorized in the EU, together with an antiviral treatment (Tecovirimat SIGA). The authorization is based on a recommendation from the European Medicines Agency (EMA), which found the vaccine to be effective and safe for this…